We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

SEC Hits Valeant With Multi-Pronged Probe

Law360 (September 11, 2006, 12:00 AM EDT) -- Valeant Pharmaceuticals International announced Monday that the U.S. Securities and Exchange Commission was investigating possible share trading irregularities surrounding the release of trial data for the company’s hepatitis C drug, Viramidine....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.